NK cell Immunity to Influenza

NK细胞对流感的免疫

基本信息

  • 批准号:
    7657174
  • 负责人:
  • 金额:
    $ 15.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-04-01 至 2009-03-31
  • 项目状态:
    已结题

项目摘要

Influenza A virus is a highly successful human pathogen which naturally kills millions of people and has both potential and advantage as a biological weapon. Natural killer (NK) cells are lymphocytes of innate immunity that play a critical role in early defense against viral infections and in the initiation of the adaptive-immune response. Recent advances in knowledge of the diverse receptor phenotypes of NK cells within the individual person and of functional NK-cell interactions with dendritic cells (DC), suggest that the extensive diversity of killer cell immunoglobulin-like receptor (KIR) genes in (and between) human populations is the result of selection by viruses for NK-cell and T-cell responses that reduce the severity and time of infection. Here we propose three specific aims to study the role of NK-cells and NKcell receptors (NKR) in the human response to influenza A, with the overall goal of defining genetic and other factors that provide for superior response. Under Aim 1 the in vitro NK-cell response to influenza A will be studied using peripheral blood NK cells obtained from donors whose NK-cell immunogenetics is well defined. Both cytolysis and cytokine production will be assessed using flow cytometry, Elispot and cell-killing assays. The contributions of activating and inhibitory receptors to NK cell interaction with autologous influenza-infected DC will be defined. Aim 2 focuses on the expression of KIR and other NKR by subpopulations of memory and/or activated T cells, a general phenomenon but one which varies greatly within the human population. The expression of NKR by influenza-specific CD8 ¿ T cells from different donors will be characterised. The types and combination of NKR will be defined and analyzed for selective bias. The effects that these receptors have on the anti-viral functions of the T cells will be determined. The analysis proposed under Aim 3 will use the methods and knowledge obtained under Aim 1 to characterise the NK-cell response in subjects infected with influenza A or vaccinated against influenza A. Comparisons of the response will assess the diversity of the response, its correlation with NK-cell immunogenetics and with age. New knowledge of the nature and diversity of the human NK-cell response to influenza and of the role of NKR expression on CD8 ¿ T cells will be obtained. These results could lead to new strategies for terminating influenza infections through the manipulation or stimulation of human NK-cells and/or NKR-expressin 9 T cells.
甲型流感病毒是一种非常成功的人类病原体,它自然地杀死数百万人, 作为生物武器的潜力和优势自然杀伤(NK)细胞是先天性的淋巴细胞, 免疫力在早期防御病毒感染和启动 适应性免疫反应NK细胞不同受体表型的研究进展 单个人内的NK细胞和功能性NK细胞与树突状细胞(DC)的相互作用,表明 杀伤细胞免疫球蛋白样受体(KIR)基因的广泛多样性(和之间) 人类群体的免疫应答是病毒选择NK细胞和T细胞应答的结果, 感染的严重程度和时间。在这里,我们提出了三个具体的目标,研究NK细胞和NK细胞的作用, 受体(NKR)在人类对甲型流感的反应中的作用,总体目标是定义遗传和 其他提供上级响应的因素。在目标1下,体外NK细胞对甲型流感的应答 将使用外周血NK细胞进行研究,这些NK细胞从NK细胞免疫遗传学为 定义明确。细胞溶解和细胞因子产生将使用流式细胞术、Elispot和流式细胞仪来评估。 细胞杀伤测定。活化和抑制性受体对NK细胞与 将定义自体流感感染的DC。目的2着重于KIR和其他 记忆和/或活化T细胞亚群的NKR,这是一种普遍现象, 在人类群体中差异很大。流感特异性CD 8 <$T细胞表达NKR 不同的捐赠者将被发现。将定义NKR的类型和组合, 分析选择性偏差。这些受体对T细胞抗病毒功能的影响 细胞将被确定。目标3下提出的分析将使用方法和知识 根据目的1获得,以验证感染甲型流感的受试者中的NK细胞应答,或 接种了甲型流感疫苗。响应的比较将评估响应的多样性, 其与NK细胞免疫遗传学和年龄相关。对自然资源的性质和多样性的新认识 人类NK细胞对流感的反应以及NKR在CD 8 ~ T细胞上表达的作用将是 得到了这些结果可能会导致新的战略,终止流感感染,通过 操纵或刺激人NK细胞和/或表达NKR的T细胞。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER R PARHAM其他文献

PETER R PARHAM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER R PARHAM', 18)}}的其他基金

Functional genetics of human innate immunity in the bimodal gamma delta T cell response to Epstein-Barr Virus and in education of NK cells and their re-education to respond to autologous cells
人类先天免疫的功能遗传学在双峰 γδT 细胞对 Epstein-Barr 病毒的反应以及 NK 细胞的教育及其对自体细胞作出反应的再教育中
  • 批准号:
    10326842
  • 财政年份:
    2019
  • 资助金额:
    $ 15.27万
  • 项目类别:
Functional genetics of human innate immunity in the bimodal gamma delta T cell response to Epstein-Barr Virus and in education of NK cells and their re-education to respond to autologous cells
人类先天免疫的功能遗传学在双峰 γδT 细胞对 Epstein-Barr 病毒的反应以及 NK 细胞的教育及其对自体细胞作出反应的再教育中
  • 批准号:
    10552637
  • 财政年份:
    2019
  • 资助金额:
    $ 15.27万
  • 项目类别:
Insights into immune-related disease born from population genomics
对群体基因组学产生的免疫相关疾病的见解
  • 批准号:
    8105084
  • 财政年份:
    2010
  • 资助金额:
    $ 15.27万
  • 项目类别:
Insights into immune-related disease born from population genomics
对群体基因组学产生的免疫相关疾病的见解
  • 批准号:
    8292223
  • 财政年份:
    2010
  • 资助金额:
    $ 15.27万
  • 项目类别:
Insights into immune-related disease born from population genomics
对群体基因组学产生的免疫相关疾病的见解
  • 批准号:
    8486379
  • 财政年份:
    2010
  • 资助金额:
    $ 15.27万
  • 项目类别:
Insights into immune-related disease born from population genomics
对群体基因组学产生的免疫相关疾病的见解
  • 批准号:
    7992673
  • 财政年份:
    2010
  • 资助金额:
    $ 15.27万
  • 项目类别:
Insights into immune-related disease born from population genomics
对群体基因组学产生的免疫相关疾病的见解
  • 批准号:
    8676643
  • 财政年份:
    2010
  • 资助金额:
    $ 15.27万
  • 项目类别:
Insights into immune-related disease born from population genomics
对群体基因组学产生的免疫相关疾病的见解
  • 批准号:
    9307690
  • 财政年份:
    2010
  • 资助金额:
    $ 15.27万
  • 项目类别:
Insights into immune-related disease born from population genomics
对群体基因组学产生的免疫相关疾病的见解
  • 批准号:
    9100613
  • 财政年份:
    2010
  • 资助金额:
    $ 15.27万
  • 项目类别:
MHC CLASS I AND KIR GENE EVOLUTION IN HIGHER PRIMATES
高等灵长类动物 MHC I 类和 KIR 基因的进化
  • 批准号:
    7349828
  • 财政年份:
    2006
  • 资助金额:
    $ 15.27万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 15.27万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 15.27万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.27万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了